Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective
作者： Tal Zaks
DOI: 10.1007/978-1-60327-088-5_18
关键词:
摘要: The elucidation of the human genome sequence and advent genomic technologies have potential to facilitate drug discovery development as well define individual risks benefits associated with specific therapeutic interventions. This chapter focuses on application this knowledge within pharmaceutical industry, by providing current examples relevance both germline somatic genotypic variations adverse event efficacy profiles recently developed anti-cancer drugs. These examples, discussed scientific, regulatory, economic frameworks that shape highlight emerging challenges post-genomic science “real-life” development.
springer.com
sci-hub.st 参考文章(53)
Gregory S Merrick, Kent E Wallner, Wayne M Butler, Management of Sexual Dysfunction After Prostate Brachytherapy Oncology. ,vol. 17, pp. 52- 62 ,(2003)
Lon R Cardon, Ramana M Idury, Timothy JR Harris, John S Witte, Robert C Elston, None, Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics. ,vol. 10, pp. 503- 510 ,(2000) , 10.1097/00008571-200008000-00003
William S Dalton, Stephen H Friend, Cancer biomarkers--an invitation to the table. Science. ,vol. 312, pp. 1165- 1168 ,(2006) , 10.1126/SCIENCE.1125948
James H. Ware, The limitations of risk factors as prognostic tools. The New England Journal of Medicine. ,vol. 355, pp. 2615- 2617 ,(2006) , 10.1056/NEJMP068249
Frédérique Penault-Llorca, Anne Cayre, Laurent Arnould, Frédéric Bibeau, Marie-Pierre Bralet, Philippe Rochaix, Jacqueline Savary, Jean-Christophe Sabourin, Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment Oncology Reports. ,vol. 16, pp. 1173- 1179 ,(2006) , 10.3892/OR.16.6.1173
Gong Yang, Yu-Tang Gao, Qiu-Yin Cai, Xiao-Ou Shu, Jia-Rong Cheng, Wei Zheng, Modifying effects of sulfotransferase 1A1 gene polymorphism on the association of breast cancer risk with body mass index or endogenous steroid hormones. Breast Cancer Research and Treatment. ,vol. 94, pp. 63- 70 ,(2005) , 10.1007/S10549-005-7280-2
David A Campbell, James Carmichael, Rajesh Chopra, Molecular pathology in oncology--the AstraZeneca perspective. Pharmacogenomics. ,vol. 5, pp. 1167- 1173 ,(2004) , 10.1517/14622416.5.8.1167
L.C. AMLER, A.D. GODDARD, K.J. HILLAN, Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Cold Spring Harbor Symposia on Quantitative Biology. ,vol. 70, pp. 483- 488 ,(2005) , 10.1101/SQB.2005.70.048
R A Salerno, L J Lesko, Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics Journal. ,vol. 6, pp. 78- 81 ,(2006) , 10.1038/SJ.TPJ.6500345
Primo N. Lara, Karen Giselle Chee, Jeff Longmate, Christopher Ruel, Frederick J. Meyers, Carl R. Gray, Regina Gandour Edwards, Paul H. Gumerlock, Przemyslaw Twardowski, James H. Doroshow, David R. Gandara, Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. ,vol. 100, pp. 2125- 2131 ,(2004) , 10.1002/CNCR.20228